+ Watch TRGT
on My Watchlist
A biopharmaceutical company engaged in the design, discovery and development of NNR Therapeutics, a new class of drugs for the treatment of multiple diseases and disorders of the central nervous system.
Here's a classic, I'm afraid. This stock is up 500% on some good milestone news. Their drug still has a way to go before final approval for marketing, and the stock is already valued 17 times earnings, bringing it to small cap range of $500M.At half a billion dollars worth, I think this stock is a little ahead of itself, and should be fairly traded more in the vicinity of 6-8 times its earnings. These are unlikely to grow in the immediate future due to the good news we've heard.
BATS data provided in real-time. NYSE, NASDAQ and NYSEMKT data delayed 15 minutes.
Real-Time prices provided by BATS. Market data provided by Interactive Data.
Company fundamental data provided by Morningstar. Earnings Estimates, Analyst Ratings and Key Statistics provided by Zacks.
SEC Filings and Insider Transactions provided by Edgar Online.
Powered and implemented by Interactive Data Managed Solutions. Terms & Conditions